Stem cell therapy for spinal cord injury (SCI) is used to treat an incurable, life-altering neurological disorder that causes permanent loss of movement and sensory function in millions of people throughout the world. It affects them in every aspect of their personal and social lives. Stem cell therapy has been recognized as a feasible treatment for SCI in the research community for the last two decades.
Stem cell therapy for spinal cord injury (SCI) has emerged as a very promising treatment. Every year, about 500,000 new cases of SCI are reported worldwide. Trauma from traffic accidents, falls, gunfire, or medical/surgical complications is the most common cause.
SCI remains a syndrome that primarily affects young people due to the nature of its causes. However, because we live in an aging society, we are seeing an increase in the frequency of new occurrences of SCI in the older population following low-energy trauma.
Current clinical therapy emphasizes early surgical decompression and mechanical stabilization of the SCI site, followed by pharmaceutical intervention with methylprednisolone, nimodipine, naloxone, and other medications. Patients enroll in rehabilitation programs after the initial critical period to regain functionality and autonomy.
Unfortunately, all of these therapies have yielded poor results in terms of neuroprotection, neuroregeneration, and functional recovery. The complexity of the pathophysiological mechanisms of SCI, which result in irreparable damage to the neuronal environment at the site of the lesion, is to blame for this failure.
Stem cell therapy trials using humans with SCI became a reality in the first decade of this century and yielded excellent outcomes.
The exact mechanism of spinal cord injury (SCI) is separated into two stages. The first, known as primary injury, occurs when a mechanical force is applied to the spinal cord, producing compression, laceration, distraction, or shearing of neuronal tissue as well as damage to blood vessels and surrounding tissues. According to research, primary damage almost never fully breaks the spinal cord’s anatomical continuity.
Secondary injury is further classified into four stages: immediate (0-2 hours after the injury), acute (2-48 hours, subacute: 2 days – 2 weeks), intermediate (2 weeks – 6 months), and chronic (>6 months).
The first visible change is a widespread swelling of the spinal cord, which is accompanied by hemorrhage in the central gray matter. Direct breakdown of cell membranes and ischemia caused by vascular damage result in cell necrotic death, which leads to white matter hemorrhage and cord ischemia that can extend to several spinal segments.
The disruption of the blood-spinal cord barrier causes neuroinflammation, which contributes to the death of brain cells.
Stemwell uses cord tissue-derived mesenchymal stem cells ethically sourced from full-term human umbilical cords (We do not utilize cells from embryos). We then administer more than 300 million cells that are all thoroughly tested for viability before treatment. These cells are NOT a blood product; therefore, it is extremely safe and does not require HLA or phenotypic matching.
Video call with our patient advocates and our doctors where the patient’s condition and medical history will be discussed.
The patient undergoes an initial evaluation and blood work by Stemwell’s doctor.
Endovenous detox therapy applied to patient
Localized intrathecal stem cell injections in trigger pain points
Hyperbaric Chamber therapy – Hyperbaric oxygen reduces inflammation, oxygenates injured muscle, and regenerates skeletal muscle via macrophage and satellite cell activation.
Photobiomodulation (PBM Therapy) – the application of red and near infra-red light over injuries or lesions to improve wound and soft tissue healing, reduce inflammation and give relief for both acute and chronic pain.
*Each Protocol is customized to the patient depending their medical and surgical history
This protocol information is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, is for general information purposes only.
Mesenchymal stem cells (MSCs) are key to stem cell therapy for spinal cord injury. They are multipotent progenitor cells that can be extracted from a variety of tissues, including bone marrow, adipose tissue, the umbilical cord, and amniotic fluid. Their use raises no ethical problems. Furthermore, they have a low tumorigenicity and immunoreactivity profile. They are believed to act at the site of the lesion by secreting a variety of substances, including growth and adhesion factors, anti-inflammatory factors, and cytokines. As a result, their effects are anti-apoptotic, neurotrophic, neuroprotective, and immunomodulatory.
The human umbilical cord is used to harvest umbilical cord mesenchymal stem cells (UCMSCs). They are easily grown in vitro and have modest immunoreactivity. Cytokines, growth factors, interleukins, BDNF, bFGF (basal Fibroblast Growth Factor), and neutrophil activators are all produced by them. When transplanted, these cells are thought to have anti-inflammatory, anti-apoptotic, neurotrophic, and proangiogenic properties.
Wharton jelly is a viscoelastic material found in the umbilical cord that serves to protect blood vessels. It is possible to harvest and cultivate Wharton-Jelly mesenchymal stem cells (WJ-MSCs). They create a number of neurotrophic factors and can promote neurogenesis and angiogenesis due to high quantities of NGF, bFGF, and GDNF released. Studies have revealed that repeated infusion of WJ-MSCs can reduce glial scar and cause spinal cord regeneration.
Regenerative stem cell therapies have a high success rate and long-term success with no hardware placement and additional loss of mobility. Stem cells appear to have the anti-inflammatory and immunomodulatory effects described above, whether injected intravenously or intrathecally. They also relieve pain and increase quality of life in spinal cord injury (SCI) patients while slowing down further degeneration and assisting in the preservation and improvement of spinal mobility.
Our mission is to bring hope, healing, and a personalized plan to every patient we meet. We believe the caring hands and expertise of our doctors along with our proven protocols provide the best possible outcomes. We follow the highest ethical international standards offering transparency, honesty, and clinical accuracy.
Stem cell therapy offers no guarantees and is not promoted as a cure. This is similar to many other medical treatments. Reviewing the patient’s medical history is necessary to determine stem cell therapy eligibility. Any personal information provided is for internal and medical use with our medical providers only. The Stemwell Health headquarters is located in McLean, Virginia. Stemwell Health Virginia is not a stem cell treatment facility or surgical center. Treatments are not conducted anywhere in the US, since these advanced therapies are not yet FDA-approved. All cell therapies are conducted in Colombia where it is regulated by the ministry of health, INVIMA (Columbia’s FDA equivalent) and other local authorities. All treatments are performed within the country’s legal limits and regulatory framework where the specific medical provider practices.
